Tumor molecular profiling plays an integral role in identifying genomic anomalies which may help in 1 6 personalizing cancer treatments, improving patient outcomes and minimizing risks associated with 1 7 different therapies. However, critical information regarding the evidence of clinical utility of such 1 8 anomalies is largely buried in biomedical literature. It is becoming prohibitive for biocurators, clinical 1 9 3 7 exception of a few well-established biomarkers such as KRAS in metastatic colorectal cancer [1-3], 3 8
there could be more terms that represent the effects, these concepts are of key concern to precision 1 4 1 oncology, explaining their prevalence in the associated literature. We will refer to them as RO entity 1 4 2 (RO stands for Response or Outcome) in this article. We treat phrases such as "significantly poorer 1 4 3 response", "survival rate", and "increased drug resistance" as RO entities. A formal definition of how 1 4 4 RO entities are detected is described later in this article in the subsection "Entity recognition". the information about the response/outcome is incomplete without the extraction of drug/treatment 1 4 7 ("Folfox chemotherapy" in Example 1) and the disease for which this treatment is being used 1 4 8 (captured by the phrase "metastatic or recurrent gastric cancer"). eGARD attempts to capture these 1 4 9 four components from text, viz., the anomaly, the response/outcome, the drug and the disease. Here, 1 5 0 all four are mentioned in the same sentence. However, this is not always the case and sometimes the 1 5 1 disease and the drug has to be inferred from the rest of the abstract. Finally, in addition to the extraction of the four components from sentence shown in Example 1, 1 7 1 as "relationship", "contribute", "(play a) role") that we use for this sentence structure, with several 1 7 2 textual variations for each trigger. As with Examples 1 and 2, the Anomaly entity and the RO entity serve as syntactic arguments of the 1 7 6 trigger word. The syntactic relations are of subject and object of the trigger, and the trigger word is a 1 7 7 9 verb. Our rules for association type sentence structure look for the syntactic pattern: <anomaly 1 7 8 entity> "trigger word" <RO entity>. Our system first identifies sentences which contain the trigger 1 7 9
word. In such cases we check if the requisite syntactic arguments of the trigger are an Anomaly entity 1 8 0 and a RO entity. In this case, the pair is extracted. As mentioned earlier, eGARD attempts to find the impact type (one of benefit, lack of benefit or non-1 8 2 assessable) from the extracted associations. In association type sentences, sometimes the trigger verb 1 8 3 is modified by an adverb which indicates the impact type. Example 2 is one such case where the 1 8 4 adverb "inversely" indicates that MGMT expression will inversely impact the temozolomide 1 8 5 response, from which we infer that high expression levels of MGMT incurs lack of benefit from 1 8 6 temozolomide. Other than "inversely", we use words "positively" and "negatively", too. If we cannot 1 8 7 determine impact type from the adverb modifier, we look into the Anomaly entity and RO entity to 1 8 8 determine the impact type. From the Anomaly entity, we detect information such as expression levels 1 8 9 by looking at adjective modifiers "low", "high", "elevated", "overexpressed" etc. or specific 1 9 0 constructs such as gene name followed by words "positive", "negative", "deficiency" etc. From the 1 9 1 RO entity, we try to detect the impact type by the presence of certain adjectives modifying the drug 1 9 2 responses, such as "poor", "better", "greater", "worse" etc. For instance, in Example 1, we detect the 1 9 3 expression level of Bax as "low" from the Anomaly entity and drug response as "poor" from the RO 1 9 4 entity. Combining both, we infer that low expression of Bax incur lack of benefit for drug response. This type of sentence also expresses an association relation between Anomaly entity and RO entity 1 9 8 except that the relation is expressed with a comparison. These types of sentences are very common in 1 9 9 1 0 biomedical literature, especially in the pharmacogenomics domain. Unlike the association sentence 2 0 0 type, there are three entities involved in the comparison sentence type: an observed entity and two 2 0 1 compared entities. We are interested in comparison sentences where an observed entity is an RO 2 0 2 entity and the two compared entities are related to the Anomaly entity (as in Example 3 below) or 2 0 3 vice-versa. In Example 3, the observed entity is indicated by the phrase "better PFS ( P = 0016 ) and OS ( P = 2 0 7 0030 )", and the two compared entities are "ERCC1-negative patients" and "positive patients", 2 0 8 respectively. Therefore, this comparison marks an association between ERCC1 expression level and 2 0 9 survival of patients. To recognize and extract information from comparison sentences, we look for two clues. First, we 2 1 1 consider the trigger to be a comparative adjective (with the part of speech of JJR in the parse 2 1 2 structure) such as higher, lower, greater, better etc. ("better" in Example 3). Then, we look for phrases 2 1 3 such as "compared with", "in comparison to", "compared to", "than" and "versus" which often 2 1 4 separates the two compared entities. The comparative adjective is connected to the observed entity in one of two ways. It can modify the observed entity which appears as noun to its right as in Example 3. The syntactic pattern that 2 1 7 corresponds to Example 3 is: <Anomaly entity> "trigger" <RO entity> comparison_phrase 2 1 8 <Anomaly entity>. Alternatively, the comparative adjective can appear as the head predicate of a 2 1 9 sentence as in Example 4 and in these cases, its subject (TS and TP mRNA levels in Example 4) is 2 2 0 extracted as the observed entity. The syntactic pattern that corresponds to Example 4 is: <Anomaly 2 2 1 1 1 entity> in <RO entity> "trigger" comparison_phrase <RO entity>. Note that in either case, one of 2 2 2 the two compared entities appears immediately after the comparison phrase ("compared with", 2 2 3 "compared to", "than" etc.). The other argument will be either the subject when the JJR modifies a 2 2 4 noun or as an adjunct of the subject when it appears as the head predicate (Example 4). Example 4: "TS and TP mRNA levels in the patients with complete response, partial response 2 2 6 or stable disease (n = 34) were significantly lower compared to those in the patients with 2 2 7 progressive disease (n = 11) (p = 0017 and p = 004, respectively)." (PMID: 22783377) compared entities is explicitly mentioned in the sentence. In such cases, the implicit compared entity entities is missing in the sentence, but implicitly referred to as groups with high level of TS. The impact type in comparison sentences are detected by combining information presented in the 2 3 5 trigger (the comparative adjective) and in both Anomaly and RO entities. In the case where the 2 3 6 observed entity is the RO Entity (as in Example 3), we detect the expression levels or specific 2 3 7 mutations from the Anomaly entity and the impact type from the trigger. Additionally, we recognize 2 3 8 the type of the RO entity so that we can correctly qualify the impact type. Let's consider Example 3 2 3 9
to illustrate our approach. The Anomaly entity ("ERCC1-negative patients") specifies low expression 2 4 0 of ERCC1, the trigger "better" specifies a positive correlation and finally, the RO entity ("PFS ( P = 2 4 1 0016 ) and OS (P = 0030)") specifies the outcome as survival type (PFS and OS stands for 2 4 2 progression-free and overall survival, respectively, determined by the use of an acronym detector). Combining all of them, we infer that low expression ERCC1 incurs benefit for the drug response. However, if the observed entity is the Anomaly entity (as in Example 4), the trigger indicates the 2 4 5 expression levels and the first compared entity (which is a RO entity) hints about the impact type. In Example 4, the trigger "lower" represents the expression levels for Anomaly entity ("TS and TP 2 4 7 mRNA levels") and the RO entity ("patients with complete response, partial response or stable 2 4 8 disease") represents response of patients. Combining both, we infer that low levels of TS and TP incur benefit for the drug response. Words like "resist" or "sensitive" can appear in their noun form as RO terms in the association type 2 5 3 sentences as in Example 6 for instance. However, the verb forms of these words are also often used in sentences that connect them with 2 5 7
Anomaly entities. These verbs appear as the head predicate of the clause with the Anomaly entities as 2 5 8 their subjects. Our rules for extraction look for the following syntactic pattern: <anomaly entity> 2 5 9 sensitizes <disease (cells)> to <drug/treatment> as shown in Example 7. That is, the trigger appears 2 6 0 as verb (VBN) with the Anomaly entity appears as its subject and the disease cells as a direct object. The drug or treatment phrase appears as a prepositional phrase modifying the trigger with the 2 6 2 preposition "to". Sometimes, the disease cells that are sensitized are not mentioned in the sentence. In such cases, as 2 6 6 discussed later, the disease is inferred from the context. Detection of impact type from sensitization type sentences is fairly straight-forward. In the syntactic 2 6 8 pattern mentioned above, as the trigger "sensitize" suggests that the Anomaly entity causes the 2 6 9 disease cells to respond to the drug, the Anomaly entity always incurs benefit for the drug response. Therefore, it is sufficient to look only at the Anomaly entity involved and determine the expression 2 7 1 levels or specific mutations that cause the benefit. For example, the Anomaly entity ("ATM 2 7 2 deficiency") refers to low levels of ATM. Thus, low expression of ATM incurs benefit for the drug 2 7 3 response. In this type of sentence structures, we consider cases where the genomic anomalies are stated to be 2 7 7 markers for drug responses. These relationships are triggered by words such as "predictor", 2 7 8 "biomarker", "marker", "indicator" etc. For instance, the sentence in Example 8 is of this type of 2 7 9 sentences with trigger word "predictor". Example 8: "Multivariate analysis showed that low expression of ERCC1 was an independent 2 8 1 predictor for prolonged survival (HR, 0120 ; 95% CI , 0016-0934 , P = 0043) ." A key requirement for these sentences is the presence of an "is-a" verb group. We have adopted the 2 8 4 approach mentioned in miRiaD [46] , which uses "is a", "are", "acts as", "functions as", "serves as" 2 8 5 and appositives as triggers for the "is-a" relation. The Anomaly entity is found as the subject of "is-a" 2 8 6 and the "marker" trigger is its object. The RO entity is found as the noun modifier for the trigger 2 8 7 often linked with the preposition "for". Using this rule, from Example 8, we can extract "low 2 8 8 expression of ERCC1" as the Anomaly entity (from which the gene and anomaly are obtained), 2 8 9 "prolonged survival" as the RO entity. Given the nature of copular sentences, we can detect variations of this type of sentences where the 2 9 1 trigger might be an adjective (JJ) instead of noun, such as "predictive", and "indicative". Example 9 2 9 2 presents one such sentence where the trigger is the adjective "predictive". Example 9: "Furthermore, concomitant low expression levels of ERCC1, RRM1, and RRM2 2 9 4 and the high expression level of BRCA1 were predictive of a better outcome (P = 0014). " Impact type detection in these cases is identical to impact type detection in association type, where 2 9 7 we combine information from both the Anomaly and RO entity and infer the impact type. For 2 9 8 instance, applying the rules mentioned earlier, Example 8 will yield the information that low 2 9 9 expression of ERCC1 benefits the drug response (survival in this case). There are sentences that do not explicitly indicate the association between genomic anomaly and drug 3 0 2 responses. However, these sentences seem to present a quantitative value of an RO entity for multiple quantities, we hypothesize that there is an implicit comparison to draw an association (See Example 3 0 5 1 5 10 below). We do not detect the impact type since it can be inferred only by comparing the numbers, 3 0 6 and knowing how to interpret the numbers. Example 10: "Among cohort 2 , the response rates of patients with low ERCC1 and high 3 0 8 ERCC1 expressions were 45.5% and 20.0% respectively ( P = 0.361 )." (PMID:23358102)
Here the outcome is mentioned in terms of response rates and is connected to ERCC1 levels. then typed to different categories, which is followed by the extraction of association of genomic 3 1 5 anomaly and drug response. We additionally extract other information that helps determine the Our system takes PMIDs as input and retrieves the title, abstract and MeSH terms from MEDLINE repository. An in-house sentence splitter was used to split the abstracts into individual sentences. We terms and entities assisted the entity detection step. For instance, in the text excerpt "The median 3 2 6 disease-free survival (DFS) time was 10.2 mo in the patients." (PMID: 17854149), the term "disease-3 2 7 free survival" is a RO entity and the acronym detects the abbreviated form for it as "DFS". Thus, we 3 2 8 treated DFS as a RO entity as well throughout the abstract. The simplification step will render these simplified sentences: "High MDR1 gene expressions are 3 3 8 associated with inferior outcome" and "High ERCC1 gene expressions are associated with inferior 3 3 9 outcome". Thus, applying one simple pattern, we can extract both the relations without explicitly VGs were merged into larger VGs as well. For example, the BioNex system will parse the sentence is To detect diseases, we used annotation from Pubtator [29] , which is a publicly available tool that 3 5 3 assists biocuration by tagging various biological entities. We downloaded and used the pre-computed tagging in Pubtator, such as AR being commonly tagged as disease although its full form also 3 5 7 mentioned in the abstract is the gene Androgen Receptor. The system was able to automatically 3 5 8 rectify this type of problems using the acronym detector. The acronym detector detects AR as a short 3 5 9 form of Androgen Receptor, which in turn is detected as a Gene. By looking at the full form detected 3 6 0 by acronym detector, the system was able to discard AR a disease and consider it as a gene mention. For gene mentions, we used both Pubtator and an in-house gene mention detector pGenN [51] . The 3 6 2 gene mentions were normalized to EntrezIDs. For drug detection, we used Pubtator annotation, too. Genomic anomalies can be either mutations or change in gene expression levels. Although they are 3 6 4 biologically different, they both have the potential to impact the drug responses of a therapy. Therefore, we treat them similarly in the context of our work, grouping them together under Anomaly 3 6 6 entity. Mutations were detected using our previously built tool used in the system DiMeX [45] , which 3 6 7 also provides mutation to gene associations. Additionally, we developed a separate system to detect We developed our own module to detect gene expression level mentions as genomic anomalies. Usually expression terms appear along with the corresponding gene name in the same noun phrase, 3 7 2 with the head word of a NP indicating an expression (e.g., expression, overexpression, inhibition, 3 7 3 deficiency, levels etc.). Sometimes the expression terms are connected to the gene name via the "of" preposition (e.g "high expression of TS"). We also detect NPs as expression entities if they are where TS is a gene name). Additionally, phrases that indicate expression levels with numeric values 3 7 7 along with a gene name such as "TS <= 7.5x10 (-3)" are also detected as expression entities. The RO entities are detected by NPs headed by words that indicate response or outcome. Based on 3 7 9 our observations, we have identified several of such words, such as "survival", "prognosis", survival", "PFS", "overall survival", 'OR", "objective response rate" etc. Table 1 summarizes the tools that were used for various entity detections. Once the noun phrases (NP) are obtained from the parser, we categorize the NPs depending on the 3 9 5
entities that appear within the NP, such as gene, disease, mutation etc. We named this step as typing 3 9 6 of phrases, as the NPs are assigned an entity type. The entity type is assigned based on occurrences of 3 9 7 certain entities or keywords at the head of the NP. We took the rightmost word of an NP as the head. If multiple base NPs were merged together due to prepositional phrases attachments to form one NP, 3 9 9
we consider the head of the leftmost constituent NP to be the head of the entire merged NP. For However, in certain cases, the head of the leftmost constituent NP was not conclusive for any In the discussion of the different sentence types above, we already outlined some of the syntactic 4 1 8
patterns that we used to match against text. In this section, we will formally define the patterns and 4 1 9 discuss the matching process with an example. Let's reconsider the syntactic pattern for sensitization 4 2 0 pattern that we introduced earlier: <anomaly entity> sensitizes <disease (cells)> to 4 2 1 <drug/treatment>. This pattern can be formally broken down and written as: The common element that binds the entire pattern together is a verb group (VG) headed by the word 4 2 6
"sensitize". So, to match the pattern in text, we first searched for a (possibly merged) VG with head 4 2 7
"sensitize". As we already have the types of NPs (from the typing of phrases step), the next step is to 4 2 8 ensure that the has_subj constraint is met by finding an NP of type <Anomaly> that is a subject to the All the patterns that are used in this work are matched using this same approach. List of all patterns 4 4 0 for all sentence types are available as supporting information (S1 File). In addition to detecting association between genomic anomaly and drug responses, eGARD also 4 4 5 records the associated drug and disease. The drug and the disease may co-occur in the same sentence patterns, then they are extracted as well. However, quite often, the drug and/or disease are not 4 4 9 mentioned in the same sentence but must be inferred from the context. Based on our observations, we 4 5 0
have applied certain heuristic techniques to locate the drug(s) and disease(s) from context in such 4 5 1 cases (i.e., where they cannot be extracted from the same sentence).
5 2
Drug detection: To detect the drug that corresponds to the drug response, we looked for some simple 4 5 3 patterns at certain rhetorical zones in the abstract in the following order: title, method sentences, Result, and Conclusion); we adopted the implementation mentioned in DiMeX [45] . If we denote the 4 5 8 mention of drugs as drugname, some of the patterns that we used are but not limited to "treatment 4 5 9
with drugname", "patients treated with drugname", "patients receiving drugname", "drugname 4 6 0 therapy", "efficacy of drugname" etc. The intuition behind these patterns was to identify the drugs 4 6 1 that were used to treat patients, rather than just looking for co-occurrence of drugs. The full list of 4 6 2 patterns used is available as supporting information (S1 File). provided such a sentence occurs before the current sentence. If the disease is not found in a PC 4 6 6 2 3 sentence, we look for the central disease at other rhetorical zones in the abstract in the following 4 6 7 order: title, conclusion sentence(s) and introduction sentence(s). In addition to the extraction of the association of genomic anomaly and drug responses, we also 4 7 1 extracted additional information that we believe would be helpful for a curator or a researcher to associated with a predictive biomarker. Firstly, we extract information related to patients in the study, on cell lines or models) and hence can be used to prioritize curation or rank the importance of the 4 8 0 extracted conclusion. We also look for NPs of type <cell> or <cell-lines> (given by the typing of 4 8 1 phrases step) and tag the abstract as being related to cell type study instead of patient study.
8 2
Additionally, we look for the presence of certain information (in the form of words or phrases) in the 4 8 3 abstract that provide valuable insight for a curator or a researcher to filter or rank information. These phrases or their minor variations against abstract text. Finally, we check if the publication is a review on drug response had already been annotated during a previous curation work [12] . The curated 5 0 0 information had been recorded along with the articles' PMID and sentences in the abstract that 5 0 1 conveyed the information. This curation was done by one of the authors, a domain expert who did not 5 0 2 participate in the design and implementation of the eGARD system. The same author was able to 5 0 3 quickly convert the information into annotated dataset that could be used for evaluation. We called drug and the disease. Furthermore, the type of impact (benefit, lack of benefit or not assessable) of the 5 0 7
anomaly on the response is also recorded. The abstracts in InHouseSet1 pertain to seven gene-drug 5 0 8
combinations. The list of these seven gene-drug combinations is available as supporting information 5 0 9
(S2 File). We consider the annotation to be correct only if all 4 components that are extracted by the system 5 1 1 matched with those in the annotation. The results are reported in terms of precision, recall and F-5 1 2 measure. Since the impact type can be found in the annotation only for the true positives for the 5 1 3 extraction of the 4-tuple, we separated the evaluation of the impact type from the extraction of the 4-5 1 4
tuple. Hence we considered the impact type annotations only when the system correctly extracts the 5 1 5
4-tuple and did not consider the 4-tuples incorrectly extracted by the system, which obviously will 5 1 6
not have any associated impact type information in the annotation.
1 7
We also considered a second in-house annotated dataset. A PubMed search for a biomarker gene and only 38 of the 100 abstracts in InHouseSet2 contained relevant information.
2 8
Since the primary goal of developing and using InHouse2 for evaluation was to consider the ability to reject irrelevant abstracts, determination of true negatives is important. Thus, we focus on the metric using InHouseSet2. We also provide the precision and recall results, although it must be noted that supporting information (S1 Dataset and S2 Dataset, respectively). To evaluate how well our system's performance generalizes, we considered a dataset that was not The evaluation results for PharmGKB set is presented in Table 4 . Please note that we are only able to 6 1 4 assess the recall value for this set, as it only contains positive annotations. The overall recall on the 6 1 5 100 abstracts is 0.77. Table 4 shows that similar recall scores are obtained for the two subsets: A vast amount of information regarding the association of genomic anomalies and drug responses is eGARD was applied on a large set of PubMed abstracts. We searched for combinations of 50 genes 6 2 6
and associated cancer drugs in PubMed that yielded 35,677 abstracts that contains abstract text. Table   6 2 7 5 lists some of the key characteristics from applying eGARD on those abstracts. It can be noted that 6 2 8 only 7,309 abstracts (20%) were deemed relevant by our system. From those 7,309 abstracts, our 6 2 9 system detected 20,282 associations between a genomic anomaly and a drug response. In this work, we have described a text mining system eGARD that addresses the needs and 6 3 8
challenges of automatic extraction of information regarding genomic anomalies and their impact on 6 3 9 drug treatment. Our system applies NLP techniques that capture relationships between anomalies and 6 4 0 drug responses from free text. In the field of precision medicine, such relationship will be valuable 6 4 1 for determining the right personalized treatment based on patient's molecular profile. We evaluated 6 4 2 our system on different datasets to test the extraction capabilities of the system. It achieved high 6 4 3 precision and recall (0.95 and 0.86, respectively) on finding the intended relationships from text. As it 6 4 4
is also important to minimize valuable curation time by rejecting non-relevant articles, we evaluated (from PharmGKB project), we showed that eGARD is also able to automatically reproduce 77% of 6 4 8
